The Coming Age of Personal Genetic Medicine
June 8, 2026 · Frisian News
DNA sequencing costs have dropped below $300, and companies have processed over 50 million genetic profiles. Yet personalized medicine, where your DNA determines your treatment, remains largely hype. The science only works for a handful of cancers and rare conditions.
Genomic sequencing costs have dropped dramatically, and companies like Illumina and 23andMe have processed millions of genetic profiles globally. Yet the promised era of personalized medicine, where your DNA determines your treatment, remains mostly marketing. The science works for a handful of cancers and rare genetic disorders. For the diseases killing most people, genetic data tells you almost nothing that changes how you're treated.
Pharmaceutical companies push the narrative hard. If your disease is genetic, the story goes, then the cure must be a $500,000 gene therapy sold only to the wealthy. Hospitals and insurers have invested billions in genomic testing infrastructure. The venture capital flowing into biotech startups is enormous. None of this money moves without the promise of personalized medicine as the future. The promise sells stock.
The reality is messier. Knowing you carry a BRCA mutation helps with breast cancer screening and prevention. A handful of genetic disorders now have effective gene therapies. But most human disease depends on environment, luck, and behaviors genetic testing cannot predict. Research has found that adding genetic risk scores to standard heart disease screening rarely changes treatment decisions. The media headlines ignored such findings.
Genetic medicine will widen the gap between wealthy and poor countries. Rich patients will get their genome sequenced, their treatments tailored. Poor patients will get the standard drug from 1995. Governments in wealthy nations are already building national genomic databases, a different kind of infrastructure: storing your genetic code in state computers. China has done this for Uyghurs. The potential for abuse is real, and it barely registers in the enthusiasm.
Personal genetic medicine is not a conspiracy. The science is real for specific conditions. But the gap between what this technology can actually do and what venture capitalists and pharmaceutical executives claim it will do is enormous. Before we remake healthcare around genetic destiny, we should ask why the people profiting from it have such strong incentives to oversell. That question matters more than the test results.
Published June 8, 2026 · Frisian News